1. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.
- Author
-
Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, and Pérez V
- Subjects
- Adolescent, Adult, Bipolar Disorder diagnosis, Bipolar Disorder epidemiology, Borderline Personality Disorder diagnosis, Borderline Personality Disorder epidemiology, Comorbidity, Depressive Disorder, Major diagnosis, Depressive Disorder, Major epidemiology, Disruptive, Impulse Control, and Conduct Disorders diagnosis, Disruptive, Impulse Control, and Conduct Disorders epidemiology, Double-Blind Method, Humans, Middle Aged, Neurocognitive Disorders epidemiology, Psychoses, Substance-Induced diagnosis, Psychoses, Substance-Induced epidemiology, Schizophrenia diagnosis, Schizophrenia epidemiology, Substance-Related Disorders diagnosis, Substance-Related Disorders epidemiology, Surveys and Questionnaires, Antipsychotic Agents therapeutic use, Borderline Personality Disorder drug therapy, Piperazines therapeutic use, Thiazoles therapeutic use
- Abstract
Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with borderline personality disorder., Method: Sixty DSM-IV borderline personality disorder patients were included from March 2004 to April 2006 in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a 2-week baseline period. The Clinical Global Impressions scale for use in borderline personality disorder patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains, and clinical safety were included., Results: Analysis of variance indicated no statistically significant differences between ziprasidone and placebo in the CGI-BPD. Nor were significant differences observed between groups in depressive, anxiety, psychotic, or impulsive symptoms. The mean daily dose of ziprasidone was 84.1 mg/day (SD = 54.8; range, 40-200). The drug was seen to be safe, and no serious adverse effects were observed., Conclusion: This trial failed to show a significant effect of ziprasidone in patients with borderline personality disorder., Trial Registration: clinicaltrials.gov Identifier: NCT00635921.
- Published
- 2008
- Full Text
- View/download PDF